[Modulation of the tumoral progression by anti-idiotypic antibodies of angiogenesis factors].
We took advantage of the anti-idiotypic strategy to design circulating probes mimicking the biological effects of VEGF (vascular endothelial growth factor) or FGF2 (fibroblast growth factor 2). The activation of the VEGF receptor KDR/flk-1 induced endothelial cell proliferation but not their migration, whereas that of the FGF receptor FGF-R1 gave opposite results. The long lasting delivery of KDR/flk-1 agonists, but not that of FGF-R1, in nude mice grafted with tumor fragments enhanced the tumor volume. Microscopic examination showed an increase in both the vascularization and the proliferation of cancer cells. In contrast, no difference in cell proliferation was observed within normal tissues.
Ortéga
N
N
Laboratoire de biologie moléculaire eucaryote, CNRS UPR 9006, Toulouse, France.
Jonca
F
F
Vincent
S
S
Favard
C
C
Malavaud
B
B
Bertrand
N
N
Mazerolles
C
C
Richmann
P
P
Pouliquen
Y
Y
Sarrammon
J P
JP
Ruchoux
M M
MM
Plouët
J
J
D000230:Adenocarcinoma / Q000473:pathology*; D043925:Angiogenesis Inducing Agents / Q000276:immunology*; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D016228:Endothelial Growth Factors / Q000494:pharmacology; D005346:Fibroblast Growth Factors / Q000494:pharmacology; D008222:Lymphokines / Q000494:pharmacology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D011471:Prostatic Neoplasms / Q000473:pathology*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D043925:Angiogenesis Inducing Agents; D000888:Antibodies, Anti-Idiotypic; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D005346:Fibroblast Growth Factors
Modulation de la progression tumorale par des anticorps anti-idiotypiques de facteurs angiogéniques.